dulera is a dog

Quote












Look, it's a dog. Accept it. Smile and tell your CTM and DCO how great it is, speak up happily at the meetings and tell everyone how great it is. Don't you dare be honest about this dog, it's pig cousins, Zetia and Vytorin, or anything else. Collect your paychecks, pretend to like your boss and employer and accept the fact that you're on a sinking ship with no land on the horizon.
 


















Anonymous said:
Is anyone having any success stories out there? Doing everything I can but the scripts are few and far between!
Click to expand...

When Timney starting harping about launch "Excellence", Saphris and Dulera quickly come to mind. Due to timing and acquisition announcement, it was too late for the Saphris launch to be tweaked. Timing for Dulera was also bad, however the SP marketing leads CHOSE not to listen to the advice given by their Merck colleagues for a successful launch. The SP motto, "In Agency We Trust".

Good heavens, Merck already had a 4 billion dollar product in the space and knew KOLs, SOLs, was well situated with specialty societies which screamed "leverage". Unfortunately the agency had different plans and took a different path.

That's why there was no scientific platform developed for a new entry until well after launch. Basically we were lead to slaughter with a new "me too" product because they never developed a compelling medical/scientific strategy to promote Dulera. The lack of a scientific platform speaks loudly to us as well as our customers.

Bocepravir was/is also in disarray so now they're trying to play catch up. The problem is there are less and less funds around to use to "catch up". It's not only reps hurt by the failed products and weak acquisition, there's less available to grow share and launch with. The employees are paying for the merger with loss of jobs (internal and field), lower merit increases, less SIP, reduced & more costly benefits and a total loss of morale. Say what you will about Merck but it is a wispy shadow of what it once was.

Is bocperavir the last great hope of the Merck - SP debacle?
 






Anonymous said:
When Timney starting harping about launch "Excellence", Saphris and Dulera quickly come to mind. Due to timing and acquisition announcement, it was too late for the Saphris launch to be tweaked. Timing for Dulera was also bad, however the SP marketing leads CHOSE not to listen to the advice given by their Merck colleagues for a successful launch. The SP motto, "In Agency We Trust".

Good heavens, Merck already had a 4 billion dollar product in the space and knew KOLs, SOLs, was well situated with specialty societies which screamed "leverage". Unfortunately the agency had different plans and took a different path.

That's why there was no scientific platform developed for a new entry until well after launch. Basically we were lead to slaughter with a new "me too" product because they never developed a compelling medical/scientific strategy to promote Dulera. The lack of a scientific platform speaks loudly to us as well as our customers.

Bocepravir was/is also in disarray so now they're trying to play catch up. The problem is there are less and less funds around to use to "catch up". It's not only reps hurt by the failed products and weak acquisition, there's less available to grow share and launch with. The employees are paying for the merger with loss of jobs (internal and field), lower merit increases, less SIP, reduced & more costly benefits and a total loss of morale. Say what you will about Merck but it is a wispy shadow of what it once was.

Is bocperavir the last great hope of the Merck - SP debacle?
Click to expand...

What "compelling medical/scientific strategy" could there be for Dulera? Other than the "2 co-primary endpoints", there is nothing else to talk about. This is a "me-too" no matter how you spin it.
 












How many expected that Dulera would be anything other than a me-too? Agree that the acid test of the company will come from boceprivir. Neck and neck for timing with teleprevir and requiring skillful marketing and salesmanship to keep the focus on the positive relative to its competition. A good challenge with big stakes.
 
























You have done away with your tenured salesforce who knows how to launch a new drug! It may not be such a dog afterall but when you have caterers and cocktail waitresses selling it what do you expect! How do you feel about Dulera Dr.? Can I get you another cup of Starbucks and could you give me just one script from commercial insurance? My Ass!
 






Top Bottom
Back
Quote